the documentation of disease side effects and complications surrounding treatment (eg, chemotherapy-induced neutropenia, fatigue, anemia of chronic disease), and of nonspecialty codes (eg, diabetes, hypertension). These comorbidities will be assessed
Search Results
Development of a Hematology/Oncology ICD-10 Documentation Job Aid
Daniel B. Martin, Sean Silas, Audrey Covner, Paul C. Hendrie, and F. Marc Stewart
EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance
Michael Cecchini, Jeffrey Sklar, and Jill Lacy
-line FOLFIRINOX. After 38 weeks, imaging again showed progression of hepatic metastases. He received third-line therapy with docetaxel and irinotecan for 2 weeks, but this therapy was complicated by febrile neutropenia. A tumor specimen from the
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, Jeffrey Hardacre, William G. Hawkins, Joseph Herman, Andrew H. Ko, Srinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer Burns, and Susan Darlow
neutropenia, fatigue, and neuropathy. Development of peripheral neuropathy was associated with longer treatment duration and greater treatment efficacy. 57 Updated results of the MPACT trial show that long-term survival is possible with gemcitabine plus
Updates in HER2-Positive and Triple-Negative Breast Cancers
Presented by: Melinda L. Telli and William J. Gradishar
these were small patient subsets. 25 Although neutropenia can be an adverse effect, growth factors can help manage this, he added. PARP Inhibitors in TNBC The NCCN Guidelines “call out” patients with BRCA mutations as candidates for 2 approved
NCCN Task Force Report: Breast Cancer in the Older Woman
Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer
older patients with breast cancer undergoing certain types of chemotherapy regimens. 21 , 118 Supportive care measures include therapies to minimize chemotherapy-related neutropenia and anemia. A meta-analysis of randomized studies evaluating primary
Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells
Robert J. Besaw, Adrienne R. Terra, Grace L. Malvar, Tobias R. Chapman, Lauren M. Hertan, and Benjamin L. Schlechter
-fluorouracil/oxaliplatin/leucovorin with intermittent treatment delays related to neutropenia and Clostridioides difficile infection, CT imaging revealed substantial progression of the pancreatic mass, now measuring 13.0 × 8.5 cm. The patient was then
Small Cell Lung Cancer
Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry M. Jahan, Marianna Koczywas, Cesar A. Moran, Harvey B. Niell, Janis O'Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin, and Charles C. Williams Jr.
aspirates and biopsies may be indicated in select patients with nucleated red blood cells on peripheral blood smear, neutropenia, or thrombocytopenia and no other evidence of metastatic disease. Bone marrow involvement as the only site of extensive
Prevention and Early Treatment of Opportunistic Viral Infections in Patients With Leukemia and Allogeneic Stem Cell Transplantation Recipients
Michael Angarone and Michael G. Ison
-associated mortality in allogeneic stem cell transplant recipients . Transplantation 1998 ; 66 : 1330 – 1334 . 52. Salzberger B Bowden RA Hackman RC . Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of
Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report
Eugene R. Przespolewski, Jeffrey Baron, Farshid Kashef, Kai Fu, Sheila N. Jani Sait, Francisco Hernandez-Ilizaliturri, and James Thompson
comanagement of her CML and CLL. She has tolerated both imatinib and venetoclax very well with only mild leukopenia, anemia, neutropenia, and nausea managed with ondansetron. At the time of writing, her response to venetoclax therapy is unknown because
Improving Health Equity and Reducing Disparities in Pediatric and Adolescent/Young Adult Oncology: In Support of Clinical Practice Guidelines
Justine M. Kahn and Melissa Beauchemin
. Blood 2011 ; 117 : 2596 – 2603 . 10.1182/blood-2010-05-285379 21079154 32. Wright JD , Neugut AI , Ananth CV , Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes . JAMA Intern
